JP2024546938A5 - - Google Patents
Info
- Publication number
- JP2024546938A5 JP2024546938A5 JP2024535875A JP2024535875A JP2024546938A5 JP 2024546938 A5 JP2024546938 A5 JP 2024546938A5 JP 2024535875 A JP2024535875 A JP 2024535875A JP 2024535875 A JP2024535875 A JP 2024535875A JP 2024546938 A5 JP2024546938 A5 JP 2024546938A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- derived
- bicytokine
- integrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265339P | 2021-12-13 | 2021-12-13 | |
| US63/265,339 | 2021-12-13 | ||
| US202263320750P | 2022-03-17 | 2022-03-17 | |
| US63/320,750 | 2022-03-17 | ||
| US202263328990P | 2022-04-08 | 2022-04-08 | |
| US63/328,990 | 2022-04-08 | ||
| PCT/US2022/081460 WO2023114775A2 (en) | 2021-12-13 | 2022-12-13 | Dual cytokine fusion proteins comprising multi-subunit cytokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546938A JP2024546938A (ja) | 2024-12-26 |
| JP2024546938A5 true JP2024546938A5 (https=) | 2025-12-22 |
Family
ID=86773585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535875A Pending JP2024546938A (ja) | 2021-12-13 | 2022-12-13 | マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230287075A1 (https=) |
| EP (1) | EP4448016A4 (https=) |
| JP (1) | JP2024546938A (https=) |
| KR (1) | KR20240156653A (https=) |
| AU (1) | AU2022410872A1 (https=) |
| CA (1) | CA3240903A1 (https=) |
| IL (1) | IL313525A (https=) |
| MX (1) | MX2024007270A (https=) |
| WO (1) | WO2023114775A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212598A1 (en) | 2019-04-19 | 2020-10-22 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2872964T3 (es) * | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| JP6333730B2 (ja) * | 2011-12-12 | 2018-05-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| KR101811050B1 (ko) * | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
-
2022
- 2022-12-13 WO PCT/US2022/081460 patent/WO2023114775A2/en not_active Ceased
- 2022-12-13 EP EP22908627.7A patent/EP4448016A4/en active Pending
- 2022-12-13 IL IL313525A patent/IL313525A/en unknown
- 2022-12-13 KR KR1020247023471A patent/KR20240156653A/ko active Pending
- 2022-12-13 JP JP2024535875A patent/JP2024546938A/ja active Pending
- 2022-12-13 AU AU2022410872A patent/AU2022410872A1/en active Pending
- 2022-12-13 US US18/065,504 patent/US20230287075A1/en not_active Abandoned
- 2022-12-13 CA CA3240903A patent/CA3240903A1/en active Pending
- 2022-12-13 MX MX2024007270A patent/MX2024007270A/es unknown
-
2024
- 2024-01-11 US US18/410,568 patent/US20240409600A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546938A5 (https=) | ||
| JP2023534847A5 (https=) | ||
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| US11192960B2 (en) | Trispecific and/or trivalent binding proteins | |
| Berger et al. | Therapeutic applications of monoclonal antibodies | |
| Kipriyanov et al. | Generation and production of engineered antibodies | |
| Brekke et al. | Therapeutic antibodies for human diseases at the dawn of the twenty-first century | |
| IL313525A (en) | Dual cytokine fusion proteins containing multisubunit cytokines | |
| JP2022524018A5 (https=) | ||
| JP6622396B2 (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| US11365260B2 (en) | Agonistic 4-1BB monoclonal antibody | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP7600327B2 (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| RU2016145906A (ru) | Модифицированные антигенсвязывающие полипептидные конструкции и их применение | |
| Roselli et al. | CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al. | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| JP2022551836A (ja) | Ｂｃｍａを標的とする抗体、二重特異性抗体及びその用途 | |
| Sadeghalvad et al. | Introduction on monoclonal antibodies | |
| JP2024513921A5 (https=) | ||
| JP2024546999A5 (https=) | ||
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| Harwardt et al. | Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| CN111662382A (zh) | 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用 |